CEO Matt Kapusta (uniQure)
Looking for leg up in hemophilia B gene therapy race, uniQure flashes data that helped lead to $2B CSL deal
In the two-headed race to develop the first gene therapy for hemophilia B, uniQure just got a major leg up.
In a late-breaking abstract at …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
